HCV TRIALS

Two once-daily drugs may help clear HCV, trials indicate.

 

MedPage Today (11/3, Gever) reported, “Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, contrasting with the three-times-per-day schedule needed for similar drugs in development,” according to separate trials. Baylor College researchers found that “at least 85 percent of patients adding narlaprevir (formerly called SCH 900518) to pegylated interferon-alfa-2b (PEGIntron) and ribavirin (Rebetol) after four weeks achieved rapid virological responses, compared with no patients receiving only interferon and ribavirin.” The “investigational compound BI 201355” produced “comparable results” in a study conducted by Johns Hopkins. Specifically, the “drug, also given once daily with interferon-ribavirin, led to HCV RNA becoming undetectable by week 12 in up to 90 percent of patients.” Notably, the aforementioned results are “from ongoing Phase II trials.”

958 Responses to “HCV TRIALS”

  1. Maurice says:

    .

    ñïàñèáî….

  2. Theodore says:

    .

    thanks for information….

  3. terrance says:

    .

    ñýíêñ çà èíôó….

  4. victor says:

    .

    ñïàñèáî çà èíôó….

  5. Matthew says:

    .

    good info!!…

  6. Marshall says:

    .

    áëàãîäàðñòâóþ….

  7. Enrique says:

    .

    áëàãîäàðåí!!…

Leave a Reply